Hepatocellular carcinoma, the most common form of primary liver cancer, is a disease of vigilance. Even when a tumor is successfully eliminated, the underlying cirrhotic liver that produced it remains fertile ground for new malignancies, and recurrence can appear either at the ablation site or anywhere else in the organ. International guidelines from the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Korean Liver Cancer Association therefore recommend serial imaging every three to six months after treatment, a schedule patients typically maintain indefinitely. Missing an early recurrence can mean the difference between another curative intervention and advanced, incurable disease.

The standard surveillance toolkit has long been a compromise. Computed tomography with intravenous contrast exposes patients to cumulative radiation and carries risks of contrast allergy and kidney injury, making it a suboptimal choice for patients who may need dozens of scans over a lifetime. Complete-protocol MRI with gadolinium-based contrast is widely considered the best imaging modality for detecting and characterizing hepatocellular carcinoma, but it is constrained by long scan times, high cost, limited scanner access, and the specialized expertise required to interpret dozens of image series. That bottleneck has motivated radiologists to ask a deceptively simple question: how much of the full scan is actually necessary?

The UCLA team, led by Pedram Keshavarz and senior authors Steven S. Raman and David S. K. Lu, tested an abbreviated MRI protocol built around just two sequences: the hepatobiliary phase of a gadoxetic acid-enhanced scan and a single-shot T2-weighted sequence. Gadoxetic acid is a liver-specific contrast agent, roughly half of which is excreted through the bile after injection. In the late hepatobiliary phase, typically captured fifteen to twenty minutes after administration, functioning hepatocytes take up the agent through organic anion transporting polypeptide transporters on their surface and appear bright. Most hepatocellular carcinomas lack these transporters, so tumors stand out as dark defects against the glowing liver, a contrast mechanism that makes the hepatobiliary phase exceptionally sensitive for cancer detection.

To evaluate the shortened protocol, the researchers assembled a retrospective cohort of 43 patients, mean age about 70 years and overwhelmingly male, who had undergone percutaneous microwave ablation for naive hepatocellular carcinoma at a tertiary care liver transplant center between January 2017 and December 2019. Nearly all had cirrhosis, most commonly from chronic hepatitis C or alcoholic liver disease. The cohort yielded 215 complete gadoxetic acid-enhanced surveillance MRI exams. Twenty-seven consecutive patients with recurrence contributed 48 positive and 86 negative exams, and 16 randomly selected patients without recurrence added another 81 negative exams, deliberately enriching the dataset with negative studies to approximate real-world screening conditions. Three board-certified abdominal radiologists, blinded to all clinical information, then independently reviewed the abbreviated versions of each exam, comparing them against the original full-protocol reports, which served as the reference standard.

The results were striking. On a per-patient basis, the abbreviated protocol achieved pooled sensitivity of 86.4 percent, specificity of 100 percent, and a negative predictive value of 88.1 percent for detecting recurrence of any type. Analyzed exam by exam, the numbers were 87.5 percent sensitivity, 97.6 percent specificity, and 93.3 percent negative predictive value, with an area under the receiver operating characteristic curve of 0.90. For recurrences confined to the ablation zone, per-patient sensitivity was 85.7 percent with perfect specificity, while for recurrences elsewhere in the liver the protocol detected 86.6 percent of cases, also with perfect specificity, though the negative predictive value for these distant recurrences dipped to 72.4 percent. Perhaps most impressive was the consistency between readers: inter-reader agreement was excellent, with a kappa of 0.91 per patient, comparable to the agreement reported for full-protocol interpretation of treated lesions.

The failures of the abbreviated scan were as informative as its successes. Across 645 readings, only three false positives occurred, attributable to motion artifact mimicking a nodule, a siderotic regenerative nodule, and a benign pseudolesion, all of which would likely be resolved by a confirmatory full MRI in clinical practice. False negatives were more numerous, eleven in total, and clustered around small recurrences measuring roughly 10 to 16 millimeters that showed arterial hyperenhancement on the complete scan but were invisible or only partially visible as defects on the hepatobiliary phase. A small minority of hepatocellular carcinomas, estimated at 5 to 10 percent, retain the transporter expression that makes them take up gadoxetic acid, the so-called green hepatocellular carcinomas, and these can evade detection on hepatobiliary-phase imaging alone.

The study builds on a growing body of evidence that abbreviated MRI works for primary screening of at-risk cirrhotic patients, where gadoxetate-enhanced abbreviated protocols have reported sensitivities in the low 80 percent range. What distinguishes the new work is its focus on secondary surveillance, the follow-up of patients already treated for hepatocellular carcinoma, a setting with far fewer published data. A Korean study by Jeon and colleagues previously found no significant difference between abbreviated and full-protocol MRI for detecting post-treatment recurrence, with per-patient sensitivity of 73.1 percent for the abbreviated approach, and the UCLA results, with higher sensitivity, reinforce the case that trimming the protocol does not meaningfully compromise cancer detection.

The clinical implications are considerable. A surveillance exam consisting of two sequences instead of the full multiphasic battery could shorten scanner time substantially, reduce per-exam cost, and expand access for the many patients who currently face months-long waits for liver MRI. Because a negative abbreviated scan reliably excludes recurrence, the authors argue, it could spare patients unnecessary comprehensive imaging, lowering both healthcare expenditure and patient burden. A positive abbreviated scan, meanwhile, would simply trigger a confirmatory complete MRI, meaning false positives carry less clinical harm than false negatives. The researchers also point to the horizon: deep learning reconstruction is already being used to denoise images and cut scan times further, and experimental synthetic contrast techniques have produced gadolinium-free contrast-enhanced MRI in as little as four minutes, compared with 28 minutes for standard protocols.

The authors are careful to note the caveats. The study was retrospective, the enriched proportion of recurrence-negative exams does not reflect a true clinical population, no formal cost or time savings were quantified, the abbreviated protocol omitted diffusion-weighted imaging, and exams spanned both 1.5 and 3 Tesla scanners. Larger prospective and multicenter trials will be needed before abbreviated protocols become standard practice. Still, for the hundreds of thousands of patients worldwide who live under the shadow of hepatocellular carcinoma recurrence, the message is hopeful: the future of surveillance may be shorter, safer, and just as sharp.

Subject of Research: Abbreviated hepatobiliary phase MRI for surveillance of hepatocellular carcinoma recurrence after microwave ablation

Article Title: Hepatobiliary phase abbreviated MRI for secondary surveillance after microwave ablation of HCC

Article References: Keshavarz, P., King, K. G., Depetris, J., Quirk, M., Kang, T. W., Sayre, J., Tong, M. J., McWilliams, J. P., Raman, S. S., & Lu, D. S. K. (2025). Hepatobiliary phase abbreviated MRI for secondary surveillance after microwave ablation of HCC. CVIR Oncology, 1(1), Article 6. https://doi.org/10.1007/s44343-025-00007-1

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00007-1

Keywords: hepatocellular carcinoma, abbreviated MRI, hepatobiliary phase, microwave ablation, secondary surveillance, gadoxetic acid, liver cancer recurrence, radiology, medical imaging, cirrhosis, negative predictive value, deep learning MRI

The research, led by Shu-jie Pang, Zhe Sun, and Da-peng Xu of the Eastern Hepatobiliary Surgery Hospital at Naval Medical University in Shanghai, together with colleagues, set out to map the microbial communities residing within hepatocellular carcinoma and to ask whether the composition of those communities differs between patients whose disease recurs very early after surgery and those who remain disease-free. The team collected tumor tissue and paired adjacent non-tumor tissue from 131 patients with hepatocellular carcinoma and subjected the samples to 16S ribosomal RNA sequencing, a technique that reads out a genetic barcode shared by all bacteria and thereby allows researchers to identify which microbial taxa are present in a sample without needing to culture the organisms in the laboratory.

The first finding addresses a lingering controversy in the field. Intratumoral bacteria have been reported in liver cancer before, but studies have disagreed about whether the microbial composition of tumors actually differs from that of the surrounding, apparently healthy liver tissue. In this cohort, the authors found that overall microbial diversity—the number of distinct bacterial types and their relative abundances—did not differ significantly between tumor and normal tissue. What did differ was composition: the identity of the bacterial players shifted between tumor and adjacent tissue, and there was marked inter-individual heterogeneity, meaning that no two patients carried quite the same intratumoral microbial signature. Bacterial composition also overlapped substantially among tumor tissue, adjacent liver tissue, and bile, a pattern consistent with the idea that the biliary tract may serve as a conduit through which microbes reach the liver parenchyma.

The pivotal result, however, emerged when the researchers stratified patients by clinical outcome. When the intratumoral microbiota of patients who experienced very early recurrence was compared with that of patients who did not, one genus stood out: Bifidobacterium. This group of anaerobic, Gram-positive bacteria—famous as a beneficial inhabitant of the healthy human gut—was significantly less abundant within the tumors of patients whose cancer came back very early. In other words, a paucity of Bifidobacterium inside the tumor was associated with the most aggressive postoperative behavior of the disease. The association held up in an external validation dataset generously provided by Professor Yilei Mao and his team at Peking Union Medical College Hospital, strengthening the case that the signal is not an artifact of a single institution’s patient population.

To confirm that the sequencing signal reflected real bacteria rather than contamination, the team turned to fluorescence in situ hybridization, or FISH. This technique uses fluorescently labeled DNA probes that bind to complementary sequences in bacterial ribosomal RNA, allowing the organisms to be visualized directly within sections of tumor tissue under the microscope. The FISH experiments confirmed the physical presence of Bifidobacterium within hepatocellular carcinoma tissue, placing the bacterium inside the tumor microenvironment rather than merely detecting stray DNA that might have been introduced during sample handling.

With the association established, the researchers probed what Bifidobacterium might actually be doing inside the tumor. They divided tumor samples into those with high versus low abundance of the genus and performed transcriptomic sequencing, which measures the activity levels of all human genes expressed in the tissue. This revealed differentially expressed genes and pathways between the two groups, along with differences in the immune cell composition of the tumors as inferred from the expression profiles. Among the most notable molecular findings was that enrichment of Bifidobacterium correlated with reduced expression of BIRC5, the gene encoding baculoviral IAP repeat containing 5, a member of the inhibitor of apoptosis protein family. BIRC5, better known in the literature as survivin, is a well-characterized antagonist of programmed cell death and is frequently overexpressed in cancers, where it helps malignant cells evade the apoptotic signals that would otherwise eliminate them.

The functional implications of that transcriptional signature were tested with two complementary tissue-based assays. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, universally abbreviated as TUNEL, detects the fragmented DNA that is a hallmark of cells undergoing apoptosis, the tightly regulated process of programmed cell death. Immunohistochemistry for cleaved caspase-3, the executioner enzyme that becomes activated only when a cell has committed to the apoptotic pathway, provided an independent readout of the same biology. Both assays told a consistent story: tumors rich in Bifidobacterium showed enhanced apoptotic activity, exactly as predicted by the reduced BIRC5 expression. The convergence of the transcriptomic data with the TUNEL and cleaved caspase-3 staining lends biochemical weight to what might otherwise have remained a purely correlational observation.

The mechanistic picture that emerges is intriguing, if still incomplete. Bifidobacterium is perhaps best known to immunologists for its role in cancer immunotherapy: prior work by other groups has shown that the abundance of this genus in the gut microbiome can determine whether mice and patients respond to immune checkpoint blockade, and fecal microbiota transplantation experiments have implicated it directly in that effect. The new study extends the relevance of this bacterium from the intestinal lumen to the interior of the tumor itself, and from the immune-activation axis to the apoptotic machinery of the cancer cell. If intratumoral Bifidobacterium suppresses survivin expression and thereby lowers the apoptotic threshold of tumor cells, its absence could plausibly permit residual malignant cells to survive the surgical insult and seed very early recurrence—although the authors are careful to note that causality has not been demonstrated and that the finding requires validation in multi-center cohorts.

Several caveats frame the interpretation of the work. The study was conducted at a single Chinese center, and liver cancer etiology varies considerably across the world, with hepatitis B virus dominating in East Asia while hepatitis C, alcohol, and nonalcoholic fatty liver disease drive the disease elsewhere; whether the microbiota-recurrence link generalizes across these different disease backgrounds remains to be seen. The 16S sequencing approach identifies bacteria only to the level of genus or species with limited resolution and cannot by itself reveal what the organisms are metabolically doing. And as with all studies of low-biomass tissues, distinguishing a genuine resident microbiota from environmental or procedural contamination is a persistent methodological challenge—one that the authors addressed with FISH confirmation and careful bioinformatics, but which continues to demand rigor across the field.

Nevertheless, the study opens a concrete translational avenue. If reduced intratumoral Bifidobacterium abundance is confirmed as a predictor of very early recurrence in larger, multi-center studies, it could eventually inform risk stratification after curative resection, identifying the patients who need the closest surveillance or adjuvant therapy. More ambitiously, the result feeds into a growing interest in microbiota-directed interventions—from probiotics to fecal microbiota transplantation—as adjuncts to cancer treatment. For now, the message is a sober and carefully documented one: the bacteria that live within liver tumors are not passive bystanders, and one familiar genus may hold a clue to why some hepatocellular carcinomas refuse to stay gone.

Subject of Research: Intratumoral microbiota and Bifidobacterium abundance in very early recurrence of hepatocellular carcinoma

Article Title: Intratumoral microbiota heterogeneity and Bifidobacterium abundance are linked to very early recurrence in hepatocellular carcinoma

Article References: Pang, S.-J., Sun, Z., Xu, D.-P., Shi, Y., Si-ma, H., Yang, N., & Yang, Y. (2026). Intratumoral microbiota heterogeneity and Bifidobacterium abundance are linked to very early recurrence in hepatocellular carcinoma. BMC Medicine. https://doi.org/10.1186/s12916-026-05271-3

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05271-3

Keywords: hepatocellular carcinoma, intratumoral microbiota, Bifidobacterium, very early recurrence, 16S rRNA sequencing, apoptosis, BIRC5, tumor microenvironment, FISH, immunohistochemistry, liver cancer, microbiome